Latest Peptides Stories
In the face of the growing obesity epidemic, much research has focused on the neuronal control of feeding behavior.
SAN MATEO, Calif., Feb. 28, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.
DUBLIN, Ireland and LEXINGTON, Massachusetts, February 28, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a complete response to the not approvable letter issued by the US Food and Drug Administration (FDA) to Jerini AG in April 2008 regarding its New Drug Application for FIRAZYR(R) (icatibant) for the treatment of acute attacks of hereditary angioedema (HAE).
BASKING RIDGE, N.J., Feb.
Deakin University medical scientists have created the world's first cancer stem cell-targeting chemical missile, placing them a step closer to creating a medical 'smart bomb' that would seek out and eradicate the root of cancer cells.
PALO ALTO, Calif., Feb. 9, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 13th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 15 at 3:00 p.m. Eastern time (12:00 p.m.
Researchers at the University at Buffalo have devised two new ways of "stapling" peptide helices to prevent these medically important molecules from losing their shape and degrading in the presence of enzymes.
WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration.
DUBLIN, December 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of FIRAZYR(R) (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). The study showed that patients receiving treatment with FIRAZYR experienced a significantly faster time to onset of symptom...